详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

101| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

研究疾病/适应症：

研究类型：

研究负责人：

研究单位： [1]Eastern Hepatobiliary Surgery Hospital, Second Military Medical University [2]Geneplus-Beijing Co. Ltd. [3]Xuanwu Hospital Capital Medical University,Beijing,Beijing,China,100053 [4]Beijing hospital,Beijing,Beijing,China,100730 [5]Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, University of Chinese Academy of Sciences (UCAS),Chongqing,Chongqing,China,401147 [6]Tongji Hospital affiliated to Tongji Medical College of Huazhong University,Wuhan,Hubei,China,430030 [7]Eastern Hepatobiliary Surgery Hospital, Second Military Medical University,Shanghai,Shanghai,China,200438

关键词： Next Generation Sequencing (NGS) Liquid biopsy Immune Checkpoint Inhibitor Whole Transcriptome Sequencing

研究目的：

To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题